TABLE 1.
Characteristics by clinical diagnosis and CSF amyloid status
| CU CSF A- (N = 376) | CU CSF A+ (N = 290) | MCI CSF A- (N = 34) | MCI CSF A+ (N=47) | Dementia CSF A+ (N=6) | ||
|---|---|---|---|---|---|---|
| Characteristic | Median (IQR)/N(%) | Median (IQR)/N(%) | Median (IQR)/N(%) | Median (IQR)/N(%) | Median (IQR)/N(%) | P-value |
|
| ||||||
| Age at CSF visit (years) | 72.4 (62.9, 78.7) | 72.5 (63.8, 77.9) | 75.1 (69.1, 81.7) | 78.5 (74.5, 84.6) | 83.7 (80.4, 85.7) | < .001 |
| Male | 207 (55.1%) | 169 (58.3%) | 22 (64.7%) | 23 (48.9%) | 6 (100%) | .119 |
| Education (years) | 14 (12, 16) | 14 (12, 16) | 13 (12, 16) | 13 (12, 16) | 12 (12, 12) | .027 |
| APOE ɛ4 positive | 64 (17.1%) | 111 (38.3%) | 7 (20.6%) | 22 (46.8%) | 2 (33.3%) | < .001 |
| Global z-score | 0.23 (−0.32, 0.87) | 0.28 (−0.32, 0.85) | −1.51 (−1.72, −0.86) | −1.22 (−1.87, −0.66) | −2.42 (−2.68, −2.15) | < .001 |
| Attention z-score | 0.27 (−0.27, 0.83) | 0.23 (−0.42, 0.86) | −1.07 (−1.81, −0.45) | −0.84 (−1.38, −0.17) | −2.87 (−2.92, −2.51) | < .001 |
| Language z-score | 0.29 (−0.30, 0.83) | 0.21 (−0.32, 0.83) | −0.76 (−2.00, −0.14) | −0.95 (−1.53, −0.24) | −1.31 (−2.39, −0.81) | < .001 |
| Memory z-score | 0.21 (−0.45, 0.87) | 0.31 (−0.36, 0.78) | −1.45 (−1.81, −0.86) | −1.18 (−1.84, −0.67) | −2.24 (−2.53, −1.55) | < .001 |
| Visual-spatial z-score | 0.15 (−0.38, 0.81) | 0.15 (−0.43, 0.74) | −0.63 (−1.54, −0.08) | −0.86 (−1.44, −0.34) | −2.03 (−2.41, −0.85) | < .001 |
| Elecsys CSF P-tau181 (pg/mL) | 19.4 (16.0, 23.6) | 15.2 (12.0, 22.8) | 21.9 (16.7, 26.0) | 21.7 (15.5, 31.2) | 26.1 (16.3, 34.4) | < .001 |
| MSD CSF P-tau181 (pg/mL) | 88.5 (70.0, 112.13) | 82.6 (55.8, 149.8) | 88.5 (70.6, 118.9) | 164.4 (88.6, 303.0) | 186.2 (143.6, 270.1) | < .001 |
| MSD CSF P-tau217 (pg/mL) | 66.5 (48.3, 90.5) | 80.6 (41.3, 183.0) | 80.9 (52.8, 114.6) | 211.7 (98.3, 484.8) | 242.7 (201.7, 558.4) | < .001 |
| Elecsys CSF Aβ1–42 (pg/mL) | 1491.0 (1214.0, 1773.3) | 744.2 (595.3, 882.1) | 1508.0 (1190.0, 2036.5) | 659.4 (483.1, 796.6) | 604.0 (502.3, 681.9) | < .001 |
Abbreviations: Aβ, amyloid-beta; A+, amyloid positive; A-, amyloid negative; APOE, Apolipoprotein E; CSF, cerebrospinal fluid; CU, cognitively unimpaired; MCI, mild cognitive impairment; MSD, Mesoscale discovery platform; P-tau181, phosphorylated tau 181; P-tau217, phosphorylated tau 217. A CSF Aβ1–42 level<1026 pg/mL was considered amyloid positive (A+). See Figures S1-S3 in the Supplement for two-group comparisons.